CTOs on the Move

Lifemark Health Group

www.lifemarkhealthgroup.ca

 
Lifemark Health Group is a diversified healthcare company in business since 1998 and has grown by acquisition over the past 13 years to include over 200 facilities across Canada.
  • Number of Employees: 1K-5K
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Watson Clinic

Watson Clinic is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Watson Clinic is based in Lakeland, FL. You can find more information on Watson Clinic at www.watsonclinic.com

New York City Health and Hospitals

NYC Health + Hospitals is the nation`s largest public health care delivery system. We are an integrated network of hospitals, trauma centers, neighborhood health centers, nursing homes, and post-acute care centers. We are a home care agency and a health plan, MetroPlus. The health system provides essential services to more than 1.4 million New Yorkers every year in more than 70 patient care locations and in their homes. Our talented workforce of more than 40,000 represents the diversity of our city and the communities we serve. The excellence of our staff, and our continued mission to care for all without exception, make us unique and rightly positioned to provide equitable, high-quality, culturally responsive, and affordable health care in every New York City community. Our promise to New Yorkers: Empower every New Yorker – without exception – to live the healthiest life possible by providing equitable, high quality, culturally responsive, and affordable health care in every community.

Saint Francis Healthcare System

St. Francis Healthcare System of Hawaii offers diverse opportunities to use your skills and experience to serve others and to grow professionally and personally with us

SarahCare of Jenkintown

SarahCare is a company that provides home health care, hospice services, and an adult day care center facility in the Jenkintown and Malvern areas.

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.